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Ricin toxin, an extremely potent and heat-stable toxin produced from the bean of the ubiquitous Ricinus communis (castor bean
plant), has been categorized by the US Centers for Disease Control and Prevention (CDC) as a category B biothreat agent that is
moderately easy to disseminate. Ricin has the potential to be used as an agent of biological warfare and bioterrorism. Therefore,
there is a critical need for continued development of ricin countermeasures. A safe and eﬀective prophylactic vaccine against
ricin that was FDA approved for “at risk” individuals would be an important ﬁrst step in assuring the availability of medical
countermeasures against ricin.
1.Introduction
In the aftermath of September 11, 2001, it has become in-
creasingly clear that there is a need to enhance readiness
against attack from both state sponsors and nonstate spon-
sors of bioterrorism. Ricin toxin, an extremely potent and
heat-stable toxin produced from the bean of the Ricinus com-
munis(castorbeanplant)[1],hasbeencategorizedbytheUS
Centers for Disease Control and Prevention (CDC) as a cate-
gory B biothreat agent for biological warfare and bioterror-
ism[2].Infact,accordingtoCooksonandNottingham,ricin
was code named compound W and considered for weapon-
ization during the US oﬀensive Biological Warfare Program
[3]. The US intelligence community believes that ricin was a
component of the biowarfare program of the former Soviet
Union, Iraq, and possibly other countries as well [4, 5].
Ricin toxin is relatively easy to produce and potentially
lethal when delivered orally, intramuscularly, or through in-
halation [4]. While the primary large-scale threat to US mili-
tary personnel would be through powdered material that
could be inhaled, ricin has been used successfully to assassi-
nate individuals, to carry out suicide, and in 2003-2004, to
t e r r o r i z eU Sp o s t a la n dS e n a t ew o r k e r s[ 4]. This paper re-
viewstherationalefordevelopmentofricincountermeasures
and the progress toward achieving eﬀective ricin counter-
measures.
2. Background
Ricinisa65kilodalton(kDa)polypeptidetoxincomprisedof
twodissimilarpolypeptidechains(anA-chainandaB-chain)
held together by a disulﬁde bond [1, 4, 5]. The A-chain,
∼32kDa, targets the ribosome and is therefore a potent inhi-
bitor of protein synthesis [4, 5]. Consequently, the A-chain
has been classiﬁed as a ribosome-inactivating protein (RIP)
[4, 5]. The B-chain, ∼34kDa, is a galactose or an N-acetyl-
galactosamine-binding lectin that attaches to cell-surface
receptors [4, 5]. After binding and subsequent endocytosis,
the holotoxin travels through the Golgi apparatus to the
endoplasmic reticulum where the disulﬁde bond linking the
AandBc hainsisr ed uc ed.Onc ethedis ulﬁd ebo ndisb r ok e n,
the A-chain molecule is transported to the cytosol where it
inactivates the ribosome. In fact, just one ricin molecule per
cell may be suﬃcient to permanently inhibit that cell from
performing essential cellular protein synthesis [6].
Ricin holotoxin is lethal in mice, rabbits, and monkeys at
parenteral doses of 5–25µg/kg [4]. By inhalation, ricin has
an LD50 in mice, rabbits, and monkeys of 3–17µg/kg, and by2 Advances in Preventive Medicine
ingestion it has an LD50 of 20mg/kg [4]. When ricin toxin A
(RTA) chain is separated from ricin toxin B (RTB) chain and
is administered parenterally to mice, it has limited toxicity at
lower doses. RTA is approximately 1000-fold less toxic than
natural ricin at lower doses when administered parentally to
mice [7].
Ricin toxin is a potential threat to humans by three dis-
tinctroutes:aerosolizedricinviathepulmonarysystem,food
andwaterviathegastrointestinalsystem,andbioweaponized
munitions including improvised explosive devices, via skin
wounds [8, 9]. For more than 120 years, researchers have
been working on ways to both develop prophylaxis against
ricin exposure and to eﬀectively treat ricin postexposure [4].
3. EarlyWork on Ricin Vaccine and
Pretreatmentfor Ricin Exposure
Initially, as early as the 1890s, Paul Ehrlich vaccinated mice
with oral doses of ricin and then subsequently challenged the
mice with subcutaneous lethal doses of ricin [10]. Later, in
the 1940s, a formalin-inactivated holotoxin vaccine was de-
veloped by the US Army that enhanced survival in animals
[11]. This vaccine candidate did not progress past preclinical
testing. Pretreating animals with passive transfer of either
IgG polyclonal antibody [12–14] or monoclonal directed
against RTA, appeared to eﬀectively protect them from lethal
parenteral challenge to ricin [15–17]. Protection against a
lethal dose of aerosolized ricin with passive transfer of either
IgG polyclonal or monoclonal antibody directed against RTA
h a sp r o v e dt ob em o r ed i ﬃcult to achieve.
4. Progresstowarda Prophylactic
RicinVaccine
4.1. US Army Ricin Vaccine Development (1990s). Past at-
tempts to produce a ricin vaccine with an Alhydrogel-ad-
sorbed ricin toxoid [18–20]a n dad e g l y c o s y l a t e dR T A
(dgRTA) vaccine (Lot 01-0419964, PerImmune) [20–22]
suggested that although both products can induce protective
immunity against the toxin in animals, their use as vaccines
was limited by safety concerns raised during preclinical de-
velopment, the tendency to self-aggregate and precipitate
from solution, and diﬃculties associated with process and
product characterization during manufacturing. Thus, these
vaccine candidates were limited to pre-clinical testing and
never progressed to human clinical trials.
4.2. RiVax Recombinant Vaccine. RiVax, an investigational
recombinant protein RTA vaccine, was developed based on
studies with ricin and RTA [23, 24]. RiVax is essentially RTA
with two simple amino-acid substitutions, one in the LDV
amino acid sequence {amino acid residues 74–76}, hypoth-
esized to play a key role in intact RTA-induced Vascular Leak
Syndrome (amino acid 76: valine replaced by methionine),
and the other in a ribotoxic site (amino acid 80: tyrosine re-
placed with alanine) [23]. RiVax was found to have suﬃcient
preclinical safety data to proceed to a human phase I dose-
escalating study [24, 25]. The human phase I study was de-
signed as follows: 15 healthy volunteers (three groups of ﬁve)
were vaccinated three times with intramuscular (IM) RiVax
(doses were either 10µg, 33µg, or 100µg) at monthly inter-
vals [25]. Vitetta et al. demonstrated that RiVax was safe and
elicits neutralizing antibody in a cell based assay. Vitetta et al.
reported that in the low-dose group, one out of ﬁve had
neutralizing antibody, in the intermediate dose group four
out of ﬁve had neutralizing antibody, and in the high-dose
group ﬁve out of ﬁve had neutralizing antibody. In the two
higher dose groups, neutralizing antibody titers were simi-
lar but somewhat modest. Vitetta et al. estimated that the
vaccine could protect against an injected dose of ricin of
(0.3−3.0mg)orapproximately1to10–foldthehumanLD50.
However, the duration of antibody titers after three vaccina-
tions (range: 14–127 days) was suboptimal and not related to
dosing group.
WhileinitialRiVaxphaseIresultswereencouraging,vac-
cine formulation and stability remain problematic. Vitetta
etal.requiredtheuseoffourdiﬀerentvaccinelotsduring the
course of the initial 15 subject phase I study [25]. Moreover,
RiVax formulation required storage at −70◦Ci nab u ﬀer
containing 50% glycerol. Therefore, Smallshaw and Vitetta
subsequentlydeveloped a lyophilized formulation of the vac-
cine that retained immunogenicity when stored at 4◦C[ 26,
27].
A second RiVax phase I trial in 30 subjects at three dif-
ferent dose levels, utilizing an alum adjuvant formulation,
was supported by an FDA Orphan Products grant to Univer-
sity of Texas Southwestern (UTSW). As of March 29, 2011,
enrollment for the second phase I trial [28]w a sc o m p l e t e
[29]. In their SEC annual report ﬁling, Soligenix reported
that preliminary results from the second phase 1 trial indi-
cated that RiVax appeared safe at all doses tested. To date,
human immunogenicity data have not been reported. Soli-
genix also reported that they initiated a comprehensive pro-
gram to evaluate the eﬃciency of RiVax in nonhuman pri-
mates at the Tulane University Health Sciences Center [29].
4.3.RVEcRecombinantVaccine. USAMRIIDhasdevelopeda
recombinant RTA vaccine 1–33/44–198 (rRTA 1–33/44–198)
(RVEc)p r o d u c e di nEscherichia coli [30–32]. Based on pre-
clinical studies, including a pivotal repeated-dose toxicology
study in New Zealand white rabbits conducted under GLP
[33], this product was determined to have a reasonable safety
proﬁle for use in human studies. The pre-clinical testing
demonstrated no detectable ribosome inactivating protein
(RIP) activity [33] or evidence of vascular leak syndrome
(VLS) [34] .Ap h a s eI( N = 30) ﬁrst in human escalating,
multiple-dose, and single-center study to evaluate the safety
and immunogenicity of RVEc was launched at USAMRIID,
FortDetrickMD,inApril2011.ThephaseIstudyisexpected
to be completed by the ﬁrst half of 2013 [35, 36].
5. Monoclonal Antibody Pre-Clinical
Development and Proof of Concept for
Postexposure Prophylaxis
Neal et al. reported that passive prophylactic administration
(intraperitoneal {IP} injection) of GD12 (a murine IgG1Advances in Preventive Medicine 3
monoclonal antibody (Mab)—anti-RTA) when administer-
ed 24h prior to challenge was suﬃcient to protect mice
against intraperitoneal ricin challenge of 5 LD50 [37]. Neal
et al. further demonstrated that GD12 protected mice utili-
zing a backpack tumor delivery system after intragastric ricin
challenge of 5mg/kg. Neal et al. did not test GD12 in the
setting of post-exposure prophylaxis. In a follow-up study,
Neal et al. demonstrated similar protection in mice when
twoothermonoclonalantibodies,R70(anti-RTA)and24B11
(anti-RTB), were passively administered using the so-called
backpack tumor model [38]. The mice then survived chal-
lenge with intragastric ricin 5mg/kg 12–24h. In addition,
R70MabprotectedmiceafteritwasadministeredIP,12–24h
before intragastric ricin challenge of 5mg/kg.
Prigent et al. demonstrated that a combination of three
Mabs (2 anti-RTB and 1 anti-RTA) to ricin protected mice
when the three Mabs were administered intravenously (IV)
within 7.5h after ricin intranasal challenge of 5 LD50 [39].
Thus, it would appear that Prigent et al. demonstrated a
p r o o fo fc o n c e p tf o re ﬀective post-exposure prophylaxis to
lethal-dose intranasal challenge to ricin [39].
6.Small Molecule Inhibitors:Preclinical
Development andPre-ExposureProphylaxis
Stechmann et al. have recently reported on the successful
identiﬁcation of a selective small molecule inhibitor, Retro-
2, that protected mice in a ricin nasal challenge model, when
Retro-2 was administered IP one hour prior to challenge
[40].Thissmallmoleculeinhibitorisattractiveinthatitdoes
not act on the toxin itself, but rather it blocks retrograde
trans port of the toxin, a host-toxin interaction. Stechmann
etal.arguethatsinceRetro-2blocksretrogradetransportand
does not act on the toxin or the host cell itself, there is
a decreased likelihood that signiﬁcant drug resistance will
develop to Retro-2. Moreover, Retro-2 appears to be non-
toxic to HeLa cells. Small molecules inhibitors oﬀer another
promising potential avenue for the development of eﬀective
prophylaxis against ricin toxin exposure [41].
7. Rationale for Continued Development of
Ricin Countermeasures
Schepetal.haverecentlyarguedsomewhatsimplisticallythat
although ricin is toxic, it does not deserve to be a priority in
biological countermeasure development [9]. They maintain
that bioterrorists do not possess the technical and logistical
skills necessary to formulate and mill ricin powder. St. Geo-
rgiev similarly maintained that ricin is more compatible with
a tool of assassination instead of a weapon of mass destruc-
tion[42].However,RadosavljevicandBelojevichaverecently
formulated a much more compelling and comprehensive ap-
proach to biodefense prioritization and risk assessment [8].
Their approach incorporates all of the potential biothreat
agents on the CDC biothreat agent list. Furthermore, their
model considers quantitative and qualitative parameters in
assessing risk and has four main components: perpetrators
(government institutions/organizations, terrorist groups,
individuals); agent (CDC categories A, B, and C); means and
media of delivery (air, food, water, fomites); target (direct
and indirect) [8].
The US Armed Forces, Department of Homeland Sec-
urity (DHS) personnel, ﬁrst responders, FBI, local law en-
forcement personnel, CDC/HHS, the Environmental Protec-
tion Agency (EPA), and environmental clean-up crews all
needadequateprotectionagainstpotentialbiologicalwarfare
and bioterrorism. Therefore, there is a critical need for con-
tinued development of ricin countermeasures.
8. Conclusion
While small molecule inhibitors and Mabs for post-exposure
treatment are still being evaluated in a pre-clinical setting,
RiVax has been studied in two phase I clinical trials, and
RVEc is currently in a phase I human trials. A safe and eﬀec-
tive prophylactic vaccine against ricin that is FDA approved
for “at risk” individuals should be an important ﬁrst step in
countering this 120-year-old threat.
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